Akers Biosciences Inc. (AKER) Financials Nov 14, 2014, 4:00 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Akers Biosciences Inc.
Fiscal year is January-December. All values GBP millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 1.18M 1.98M 1.11M 960,731 2.29M
Cost of Goods Sold (COGS) incl. D&A 1.01M 1.05M 792,566 883,971 1.39M
COGS excluding D&A 650,713 741,058 464,863 544,525 1.16M
Depreciation & Amortization Expense 363,563 313,506 327,704 339,446 226,728
Depreciation 54,572 92,976 93,167 71,378 61,305
Amortization of Intangibles 308,991 220,530 234,536 268,068 165,423
Gross Income 167,412 923,047 320,964 76,760 899,136
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 3.19M 1.66M 2.92M 1.8M 2.06M
Research & Development 424,257 436,992 435,680 452,581 644,107
Other SG&A 2.76M 1.22M 2.49M 1.34M 1.41M
Other Operating Expense 0 0 0 0 0
Unusual Expense 226,280 0 0 0 (58,401)
EBIT after Unusual Expense (226,280) 0 0 0 58,401
Non Operating Income/Expense 280,704 (43,746) 179,151 70,367 123,250
Non-Operating Interest Income 0 0 181 0 0
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 0 0 0 0 0
Gross Interest Expense 0 0 0 0 0
Interest Capitalized 0 0 0 0 0
Pretax Income (2.97M) (779,375) (2.42M) (1.65M) (976,763)
Income Tax 0 (183,567) (185,825) (103,101) 0
Income Tax - Current Domestic 0 (183,567) (185,825) - 0
Income Tax - Current Foreign 0 0 0 - 0
Income Tax - Deferred Domestic 0 0 0 - 0
Income Tax - Deferred Foreign 0 0 0 - 0
Income Tax Credits 0 0 0 - 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (2.97M) (595,808) (2.24M) (1.55M) (976,763)
Minority Interest Expense 0 0 0 0 0
Net Income (2.97M) (595,808) (2.24M) (1.55M) (976,763)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (2.97M) (595,808) (2.24M) (1.55M) (976,763)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (2.97M) (595,808) (2.24M) (1.55M) (976,763)
EPS (Basic) (4.00) (1.01) (1.95) (0.98) (0.61)
Basic Shares Outstanding 727,560 733,218 1.05M 1.24M 1.6M
EPS (Diluted) (4.00) (1.01) (1.95) (0.98) (0.61)
Diluted Shares Outstanding 727,560 733,218 1.05M 1.24M 1.6M
EBITDA (2.66M) (422,124) (2.27M) (1.38M) (931,687)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Akers Biosciences Inc.
Fiscal year is January-December. All values GBP millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 1.18M 1.98M 1.11M 960,731 2.29M
Cost of Goods Sold (COGS) incl. D&A 1.01M 1.05M 792,566 883,971 1.39M
COGS excluding D&A 650,713 741,058 464,863 544,525 1.16M
Depreciation & Amortization Expense 363,563 313,506 327,704 339,446 226,728
Depreciation 54,572 92,976 93,167 71,378 61,305
Amortization of Intangibles 308,991 220,530 234,536 268,068 165,423
Gross Income 167,412 923,047 320,964 76,760 899,136
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 3.19M 1.66M 2.92M 1.8M 2.06M
Research & Development 424,257 436,992 435,680 452,581 644,107
Other SG&A 2.76M 1.22M 2.49M 1.34M 1.41M
Other Operating Expense 0 0 0 0 0
Unusual Expense 226,280 0 0 0 (58,401)
EBIT after Unusual Expense (226,280) 0 0 0 58,401
Non Operating Income/Expense 280,704 (43,746) 179,151 70,367 123,250
Non-Operating Interest Income 0 0 181 0 0
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 0 0 0 0 0
Gross Interest Expense 0 0 0 0 0
Interest Capitalized 0 0 0 0 0
Pretax Income (2.97M) (779,375) (2.42M) (1.65M) (976,763)
Income Tax 0 (183,567) (185,825) (103,101) 0
Income Tax - Current Domestic 0 (183,567) (185,825) - 0
Income Tax - Current Foreign 0 0 0 - 0
Income Tax - Deferred Domestic 0 0 0 - 0
Income Tax - Deferred Foreign 0 0 0 - 0
Income Tax Credits 0 0 0 - 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (2.97M) (595,808) (2.24M) (1.55M) (976,763)
Minority Interest Expense 0 0 0 0 0
Net Income (2.97M) (595,808) (2.24M) (1.55M) (976,763)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (2.97M) (595,808) (2.24M) (1.55M) (976,763)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (2.97M) (595,808) (2.24M) (1.55M) (976,763)
EPS (Basic) (4.00) (1.01) (1.95) (0.98) (0.61)
Basic Shares Outstanding 727,560 733,218 1.05M 1.24M 1.6M
EPS (Diluted) (4.00) (1.01) (1.95) (0.98) (0.61)
Diluted Shares Outstanding 727,560 733,218 1.05M 1.24M 1.6M
EBITDA (2.66M) (422,124) (2.27M) (1.38M) (931,687)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
